

Due Diligence Report: Cancer Research From the Comfort of Your Home

Summary

Premier Biomedical, Inc., a research-based company, discovers and develops medical treatments for various health issues. The company develops Sequential-Dialysis Technique, a methodology for the removal of molecules that are harmful and responsible for causing diseases, such as cancer, muscular dystrophy, neurofibromatosis, Ebola, etc., as well as to prevent the onset of various diseases; and Feldetrex drug candidate for the treatment of fibromyalgia and neuropathy. The company intends to market its products to pharmaceutical and/or medical devices firms. Premier Biomedical, Inc. has a collaborative agreement with the University of Texas to develop a series of research and development programs for its sequential-dialysis technology in the areas of cancer, chronic pain syndrome, fibromyalgia, multiple sclerosis, amyotrophic lateral sclerosis, blood sepsis, heart attacks, and strokes. The company was founded in 2010 and is based in El Paso, Texas.

Premier Biomedical Inc. has a current market capitalization of \$0.528 M with 22.54 M outstanding shares. Its daily average volume traded is 4.38 M shares.

Key Indicators (Q3 2015)

Shares Outstanding	22.54 M
Revenue	Nil
Gross Profit	Nil
Net Loss (basic/diluted)	-0.94 M
Cash and Short-term Inv	0.03 M
Total Debt	0.13 M

Performance (6 months)



Recent News and Analysis:

The Company recently announced that they have obtained exclusive rights to the recently allowed U.S. patent application, "Sequential Extracorporeal Treatment of Bodily Fluids", covering the basic technology underpinning Premier's on-going research into new, innovative treatments for many of today's most debilitating diseases. Premier Biomedical, Inc. is developing a methodology for treating multiple diseases, such as cancer, which is completely different from the standard treatments now being utilized. The vast majority of presently known treatments directly inject possibly harmful agents into the body of a patient. This presents a very real risk of adverse side effects from the treatment. Premier Biomedical, Inc. intends to develop its proprietary methodology in which the pathologies are eradicated by sequentially dialyzing the patient's blood extracorporeally (outside the body). The method will utilize

designer antibodies to physically remove the pathophysiologic basis of the disease. For example, in cancer treatment, there will be the physical attachment and removal of metastasizing cancer cells, proteins or molecules which are responsible for the development, progression and metastasis of the disease. This extracorporeal methodology has an enormous potential for dramatically decreasing any side effects in the treatment of ill patients. The estimated expenditures for cancer treatment in the U.S. in 2010 were approx. \$124.5 Billion, and projected to rise to \$158 - \$175 Billion by 2020.

Though news is favorable and brought on massive daily gains of over 200% in the share price, analysts remain skeptical based on company financials and other abnormal facts. For example, the company's headquarters seems to be located in a residential house in suburban Florida. This definitely raises a red flag especially for a company that claims to be researching cancer drugs. Additionally, the Company claims to be researching ways to cure breast cancer, neurofibromatosis, atherosclerosis and muscular dystrophy. How it is managing to do so with only \$26 thousand to its name (as per Q3 financials) is not a question we can answer, but is certainly one that investors should ask themselves.

Conclusions:

While the news that BIEI published sounded grand, the company itself looks to be anything but that. This is why it will hardly be surprising to see the ticker crash right back to where it started, and maybe even further down the charts. There is the possibility that the 10-Q that BIEI delayed on the very date when its press release came out will come out and prove that the company is not as unimpressive and idle as it now seems – but I wouldn't hold my breath.

Sources:

1. <http://stockcharts.com/h-sc/ui?s=BIEI&p=D&b=5&g=0&id=p82167711507>
2. <https://ca.finance.yahoo.com/q/pr?s=BIEI>
3. <http://www.google.ca/finance?q=OTCMKTS%3ABIEI&hl=en&gl=ca&ei=QbBLVrMrI9XLjAGW37awDA>
4. <http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=BIEI.PK#bmmZ6TZpXhkbCS5p.97>
5. <http://www.hotstocked.com/article/92012/premier-biomedical-inc-otcmkts-biei-explodes-up.html>

Risk Factors

An investment in the common stock of the company is subject to a number of risks. The information below contains latest filings and risk factors that should be considered by all investors. Investors should carefully consider the risk factors set out below and consider all other information contained herein, and in the company's SEC filings, before making an investment decision. We

assume no obligation to update or revise any such forward looking statements to reflect events or circumstances that occur after such statements are made. A complete list of filings including the risk factors for the company can be found here: <http://www.sec.gov/cgi-bin/browse-edgar?CIK=prgn&Find=Search&owner=exclude&action=getcompany>

Disclosure: I, Robert Borowski, research analyst have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions and I have no business relationship with any company whose stock is mentioned in the article.

The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Robert Borowski to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor's particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

FORWARD-LOOKING STATEMENT

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Broad Street Alerts this article or report. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. All parties responsible for the creation and dissemination of this report do not engage in high frequency trading.

NO WARRANTY OR LIABILITY ASSUMED

Broad Street Alerts has not been compensated for the creation or dissemination of this report. Broad Street Alerts is not responsible for any error, mistake or shortcoming which may be occasioned at the time of printing of this document. Broad Street Alerts does not hold any positions in profiled company(s). No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. The included information is subject to change without notice.

Broad Street Alerts is the party responsible for hosting the full analyst report. Broad Street Alerts has compensated Robert Borowski seventy five dollars for the right to disseminate this report. Information in this report is fact checked and produced on a best efforts basis by Robert Borowski.